GLP-1 Peptide Atlas, by Delfa

Active not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

487

estimated

Study population

Hypertension, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Systolic BP, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06952530

Org study ID27360

Secondary IDJ2A-MC-GZL2Eli Lilly and Company

Secondary IDJ2A-MC-GZPLEli Lilly and Company

Timeline

Milestones

Study start2025-04-30actual

Study first posted2025-05-01actual

Last update posted2026-05-29actual

Primary completion2027-09estimated (month precision)

Study completion2027-09estimated (month precision)

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

HypertensionObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•refer to the GZPL master protocol study for screening eligibility.

Exclusion criteria

•refer to the GZPL master protocol study for screening eligibility.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline to Week 36

Body weight, % change

percent change from baseline, improvement

Cardiometabolic biomarkers

6 endpoints

Primary/protocol endpoint

Change from Baseline in office Systolic Blood Pressure (SBP)

Time frame:Baseline to Week 36

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP

Time frame:Baseline to Week 36

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Percent Change from Baseline in Lipids Triglycerides

Time frame:Baseline to Week 36

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Percent Change from Baseline in Lipids non-HDL Cholesterol

Time frame:Baseline to Week 36

Non-HDL cholesterol, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in hsCRP Concentration (mg/L)

Time frame:Baseline to Week 36

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Percent Change from Baseline in office SBP in Randomized Withdrawal Population

Time frame:Baseline to Week 36

Systolic BP, change

percent change from baseline, improvement

LOINC 8480-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Pharmacokinetics (PK): Steady-State Area under the Concentration Curve (AUC) of Orforglipron

Time frame:Baseline to Week 36

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.